Track Cybin Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cybin Inc. Common Stock HELP · Stock Open Cybin Inc. Common Stock in new tab

8.87 USD
EPS
-4.15
P/B
2.32
ROE
-86.94
Beta
0.62
Target Price
40.80 USD
Loading chart...
Key Metrics
Earnings dateNov. 16, 2026
EPS-4.15
Book Value3.91
Price to Book2.32
% Insiders12.901%
Estimates
Forward P/E-5.16
Forward EPS-1.76
Target Mean Price40.80

DCF valuation

Model fair value for Cybin Inc. Common Stock (HELP)
Result
Sign in to run the valuation for HELP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus None · mean target 40.80 USD (low 14.93, high 69.31) · as of 11 Nov 2026
Low 14.93
Mean 40.80
High 69.31
Price 8.87
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cybin Inc. Common Stock Logo Cybin Inc. Common Stock Analysis (HELP)

Canada Healthcare Official Website Stock

Is Cybin Inc. Common Stock a good investment? Cybin Inc. Common Stock (HELP) is currently trading at 8.87 USD. Market analysts have a consensus price target of 40.80 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cybin Inc. Common Stock is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -1.76.

Investor FAQ

Does Cybin Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cybin Inc. Common Stock?

Cybin Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -4.15.

Company Profile

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Exchange Ticker
NASDAQ HELP
CYBN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 10, 2020 0.149
Sept. 19, 2024 1:38
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion